Ferric Carboxymaltose Patent Expiration
Ferric Carboxymaltose is Used for treating iron deficiency anemia in patients with various underlying conditions using intravenous ferric carboxymaltose. It was first introduced by American Regent Inc
Ferric Carboxymaltose Patents
Given below is the list of patents protecting Ferric Carboxymaltose, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Injectafer | US10519252 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct 20, 2023
(Expired) | Am Regent |
| Injectafer | US11123321 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct 20, 2023
(Expired) | Am Regent |
| Injectafer | US11291645 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct 20, 2023
(Expired) | Am Regent |
| Injectafer | US11364260 | Methods and compositions for administration of iron | Jan 08, 2027 | Am Regent |
| Injectafer | US11433091 | Methods and compositions for administration of iron | Jan 08, 2027 | Am Regent |
| Injectafer | US11478502 | Methods and compositions for administration of iron | Jan 08, 2027 | Am Regent |
| Injectafer | US11590097 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct 20, 2023
(Expired) | Am Regent |
| Injectafer | US7612109 | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes | Feb 05, 2025 | Am Regent |
| Injectafer | US7754702 | Methods and compositions for administration of iron | Feb 15, 2028 | Am Regent |
| Injectafer | US8895612 | Methods and compositions for administration of iron | Jan 08, 2027 | Am Regent |
| Injectafer | US9376505 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct 20, 2023
(Expired) | Am Regent |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳